Physician profile
Saima Iqbal
NPI 1265605059
$2,268.87
in general payments reported to CMS, 2019-2025
23 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.01 · 2020: $24.29 · 2021: $65.69 · 2022: $344 · 2023: $519 · 2024: $498 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742 · Education: $33.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.51 |
| Education | $33.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $358.88 | 2022-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $229.93 | 2022-2025 | Terlivaz, Acthar |
| Otsuka America Pharmaceutical, INC. | $214.62 | 2019-2025 | Jynarque |
| Amgen INC. | $171.93 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $171.60 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $159.60 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $142.03 | 2022-2025 | Lupkynis |
| Vantive US Healthcare LLC | $115.87 | 2025 | Renal - Acute |
| Novartis Pharmaceuticals Corporation | $106.30 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $97.09 | 2021-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.35 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $64.05 | 2023-2024 | Ultomiris |
| Travere Therapeutics, INC. | $58.42 | 2022-2025 | |
| Horizon Therapeutics Plc | $57.58 | 2021-2022 | |
| Ardelyx, INC. | $44.08 | 2024-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.54 | 2023 | Benlysta |
| Akebia Therapeutics INC | $27.33 | 2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $25.71 | 2024 | Velphoro |
| Vifor Pharma, INC. | $24.29 | 2020 | |
| Bard Peripheral Vascular, INC. | $24.10 | 2019 | |
| Apellis Pharmaceuticals, INC. | $23.93 | 2025 | |
| Daiichi Sankyo INC. | $22.20 | 2022 | |
| Mallinckrodt Enterprises LLC | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.